Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
  • G01N33/5079—Mitochondria
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
  • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2500/00—Screening for compounds of potential therapeutic value
  • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

• Dynamic BH3 Profiling is a technique used to measure the sensitivity of cells to a test compound or therapeutic. Dynamic BH3 profiling is applied to a cancer cell sample, and drugs that move the cancer cells in that sample closer to the threshold of programmed cell death can be readily identified. The drugs so identified are those likely to provide clinical anti-cancer benefit to the subject from which the cancer cell sample was derived, thereby providing personalized therapy for individual cancer patients.
• the present disclosure relates to the discovery that the principles of dynamic BH3 profiling can be utilized to assess the toxicity of an agent in non-cancerous cells.
• the disclosure provides methods for determining how an agent alters the apoptotic sensitivity of non-cancerous cells.
• the disclosure provides a method of screening a plurality of agents for determining toxicity, said method comprising: a) providing a plurality of agents; b)providing a sample of cells, wherein the cells are non-cancerous; c) providing a test aliquot of the sample of cells for each of the plurality of agents; d) separately contacting each test aliquot with its respective agent; e) providing a control aliquot of the sample of cells, wherein the control aliquot is not contacted with any of the plurality of agents; f) permeabilizing the cells in each aliquot; g) contacting the permeabilized cells with a pro- apoptotic BH3 domain peptide; h) determining a value for percent BH3 domain peptide- induced mitochondrial outer membrane permeabilization (MOMP) in the cells in each of the test aliquots; i) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the control
• MOMP percent
• the method further comprises conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming is 20 percent or less, 18 percent or less, 16 percent or less, 14 percent or less, 12 percent or less, 10 percent or less, 8 percent or less, 6 percent or less, 4 percent or less, 2 percent or less, or 1 percent or less.
• the non-cancerous cells are healthy cells.
• the method further comprises k) providing a sample of cells, wherein the cells are cancerous; 1) providing a test aliquot of the sample of cancerous cells for each of the plurality of agents; m) separately contacting each test aliquot with its respective agent; n) providing a control aliquot of the sample of cancerous cells, wherein the control aliquot is not contacted with any of the plurality of agents; o) permeabilizing the cancerous cells in each aliquot; p)contacting the permeabilized cancerous cells with a pro-apoptotic BH3 domain peptide; q) determining a value for percent BH3 domain peptide-induced MOMP in the cancerous cells in each of the test aliquots; r) determining a value for percent BH3 domain peptide-induced MOMP in the cancerous cells in the control aliquot; and s) determining a value for delta percent priming for each of the test aliquots, wherein delta percent priming is the difference between the value for
• the method further comprises conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is greater than 20 percent, greater than 30 percent, greater than 40 percent, greater than 50 percent, greater than 60 percent, greater than 70 percent, greater than 80 percent, greater than 90 percent, greater than 95 percent, or 100 percent.
• the method further comprises conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is greater than the delta percent priming in the non-cancerous cells. In some embodiments, the method further comprises conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, or at least 200%, greater than the delta percent priming in the non-cancerous cells.
• the method further comprises conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is at least 2- fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8- fold, at least 9-fold, or at least 10-fold greater than the delta percent priming in the non- cancerous cells.
• the cancerous cells are primary human tumor cells. In some embodiments, the cancerous cells are obtained from a patient derived xenograft (PDX).
• PDX patient derived xenograft
• the plurality of agents includes 20 or more agents. In some embodiments, the plurality of agents includes 100 or more agents.
• each test aliquot is contacted with its respective agent for 24 hours or less.
• the permeabilized cells are contacted with the pro- apoptotic BH3 domain peptide for 3 hours or less.
• the cells in each of the test aliquots are permeabilized with digitonin or saponin.
• the percent BH3 domain peptide-induced MOMP is determined by one or more of: i) contacting the cells with a potentiometric dye and measuring the emission of said potentiometric dye; ii) measuring the release of a molecule from the mitochondrial intermembrane space; and iii) measuring the retention of a molecule from the mitochondrial intermembrane space.
• the potentiometric dye is 5,5',6,6'-tetrachloro-l, ,3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1),
• TMRM tetramethylrhodamine methyl ester
• the molecule from the mitochondrial intermembrane space is cytochrome c, SMAC/Diablo, Omi, adenylate kinase- 2, or apoptosis-inducing factor.
• the BH3 domain peptide is derived from the BH3 domain of a
• the BH3 domain peptide is selected from the group consisting of SEQ ID NO: 1-16.
• an agent from the plurality of agents comprises one or more compounds.
• an agent from the plurality of agents is an anticancer agent.
• an agent from the plurality of agents is a chemotherapeutic agent.
• one or more of the plurality of agents are selected from small organic molecules, small inorganic molecules, peptides, proteins, protein analogs, enzymes, nucleic acids, nucleic acid analogs, antibodies, antigens, hormones, lipids, polysaccharides, growth factors, viruses, cells, bioactive agents, pharmaceutical agents, and combinations and prodrugs thereof.
• one or more of the plurality of agents are selected from gases, fine particles, radiation, electromagnetic radiation, and aerosols.
• the disclosure provides a method of predicting toxicity of an agent to a tissue, said method comprising: a) providing an agent; b) providing a plurality of cell samples comprising non-cancerous cells, wherein each cell sample is obtained from a tissue; c) providing a test aliquot of each of the plurality of cell samples; d) separately contacting each test aliquot with the agent; e) providing a control aliquot of each of the plurality of cell samples, wherein the control aliquot is not contacted with the agent; f) permeabilizing the cells in each test aliquot and control aliquot; g) contacting the permeabilized cells with a pro- apoptotic BH3 domain peptide; h) determining a value for percent BH3 domain peptide- induced MOMP in the cells in each test aliquot; i) determining a value for percent BH3 domain peptide-induced MOMP in the cells in each control aliquot; and j) determining
• the method further comprises conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming is 20 percent or less, 18 percent or less, 16 percent or less, 14 percent or less, 12 percent or less, 10 percent or less, 8 percent or less, 6 percent or less, 4 percent or less, 2 percent or less, or 1 percent or less.
• the non-cancerous cells are healthy cells. In some embodiments, the non-cancerous cells are healthy cells. In some embodiments, the non-cancerous cells are healthy cells.
• the cells are mammalian cells. In some embodiments, the cells are derived from samples obtained by biopsy or autopsy of an animal. In some embodiments, the cells in each test aliquot are contacted with the agent for 24 hours or less. In some embodiments, the permeabilized cells are contacted with the pro- apoptotic BH3 domain peptide for 3 hours or less.
• the cells are permeabilized with digitonin or saponin.
• the percent BH3 domain peptide-induced MOMP is determined by one or more of: i) contacting the cells with a potentiometric dye and measuring the emission of said potentiometric dye; ii) measuring the release of a molecule from the mitochondrial intermembrane space; and iii) measuring the retention of a molecule from the mitochondrial intermembrane space.
• the potentiometric dye is 5,5',6,6'-tetrachloro-l, ,3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1), dihydrorhodamine 123, tetramethylrhodamine methyl ester (TMRM), or
• the molecule from the mitochondrial intermembrane space is cytochrome c, SMAC/Diablo, Omi, adenylate kinase- 2, or apoptosis-inducing factor.
• the BH3 domain peptide is derived from the BH3 domain of a
• the BH3 domain peptide is selected from the group consisting of SEQ ID NO: 1-16.
• the agent comprises one or more compounds.
• the agent is an anticancer agent.
• the agent is a chemotherapeutic agent.
• the agent is a small organic molecule, small inorganic molecule, peptide, protein, protein analog, enzyme, nucleic acid, nucleic acid analog, antibody, antigen, hormone, lipid, polysaccharide, growth factor, virus, cell, bioactive agent, pharmaceutical agent, or some combination or prodrug thereof.
• the agent is gas, fine particles, radiation, electromagnetic radiation, or aerosol.
• the disclosure provides a method of predicting toxicity of an agent, said method comprising: a) contacting an non-human animal with a sublethal dose of an agent; b)sacrificing the animal; c) providing one or more cell samples, wherein each cell sample is obtained from a tissue from the animal; d) providing a test aliquot of each of the one or more cell samples; e) separately contacting each test aliquot with the agent; f) providing a control aliquot of each of the one or more cell samples, wherein the control aliquot is not contacted with the agent; g) permeabilizing the cells in each aliquot; h) contacting the permeabilized cells with a pro-apoptotic BH3 domain peptide; i) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the test aliquot; j) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the control aliquot; and k)
• the animal is a mammal.
• the mammal is a non-human primate or a rodent.
• the animal is contacted with the agent by injection, inhalation, topical administration, or oral administration. In some embodiments, the animal is contacted with the agent for 24 hours or less.
• the permeabilized cells are contacted with the pro-apoptotic BH3 domain peptide for 3 hours or less.
• the cells are permeabilized with digitonin or saponin.
• the percent BH3 domain peptide-induced MOMP is determined by one or more of: i) contacting the cells with a potentiometric dye and measuring the emission of said potentiometric dye; ii) measuring the release of a molecule from the mitochondrial intermembrane space; and iii) measuring the retention of a molecule from the mitochondrial intermembrane space.
• the potentiometric dye is 5,5',6,6'-tetrachloro-l, ,3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1),
• TMRM tetramethylrhodamine methyl ester
• the molecule from the mitochondrial intermembrane space is cytochrome c, SMAC/Diablo, Omi, adenylate kinase- 2, or apoptosis-inducing factor.
• the BH3 domain peptide is derived from the BH3 domain of a BID, a BEVI, a BAD, a NOXA, a PUMA, a BMF, or an HRK polypeptide. In some embodiments, the BH3 domain peptide is selected from the group consisting of SEQ ID NO: 1-16.
• the agent comprises one or more compounds.
• the agent is an anticancer agent.
• the agent is a chemotherapeutic agent.
• the agent is a small organic molecule, small inorganic molecule, peptide, protein, protein analog, enzyme, nucleic acid, nucleic acid analog, antibody, antigen, hormone, lipid, polysaccharide, growth factor, virus, cell, bioactive agent, pharmaceutical agent, or some combination or prodrug thereof.
• the agent is gas, fine particles, radiation, electromagnetic radiation, or aerosol.
• the cells are cultured on an adhesive solid surface in a culture medium having serum in the presence and absence of an agent. In some embodiments of any of the provided methods, the method further comprises washing the culture media from the cells prior to contacting the cells with the BH3 profiling buffer and the pro-apoptotic BH3 domain peptide.
• the BH3 profiling buffer is added at a concentration of 2X, 3X or 4X. In some embodiments, the BH3 profiling buffer is added at a concentration of 2X and the amount of BH3 domain peptide induced MOMP is measured by microscopy. In some embodiments, the BH3 profiling buffer is added at a concentration of 3X or 4X and the amount of BH3 domain peptide induced MOMP is measured by Fluorescence-activated cell sorting (FACS).
• FACS Fluorescence-activated cell sorting
• the adhesive solid surface is coated with one or more pro- adhesive compounds.
• the one or more pro-adhesive compounds is an extracellular matrix (ECM) protein.
• ECM extracellular matrix
• the ECM protein is selected from the group consisting of collagen 1, laminin, collagen 4 and fibronectin.
• the one or more pro-adhesive compounds is an antibody.
• the one or more pro-adhesive compounds is streptavidin.
• the BH3 profiling buffer is Derived from Trehalose
• the cells are permeabilized after, prior to, or simultaneously when contacting with the BH3 domain peptide.
• the BH3 profiling buffer is
• the permeabilizing agent is digitonin or saponin.
• the permeabilizing agent is digitonin or saponin.
• FIGs. 1A-1E depict exemplary BH3 profiling on human foreskin fibroblasts (HFF).
• HFF human foreskin fibroblasts
• FIGs. 2A-2B depict exemplary drug-induced changes in BH3 profiles in healthy human foreskin fibroblasts.
• increases in cell death sensitivity were determined by BH3 profiling.
• a compound that increases apoptotic sensitivity is a compound that accelerates loss of cytochrome c.
• FIG. 2A depicts delta a histograms of the increases in cell death sensitivity (delta percent priming), with FIG. 2B depicting a zoomed view of the y-axis (percentage of compounds in the library) in 2A.
• FIG. 3 shows an exemplary comparison of drug induced changes in BH3 profiles between mouse mammary tumor cells (y-axis) and healthy human foreskin fibroblasts.
• y-axis mouse mammary tumor cells
• FIG. 3 shows an exemplary comparison of drug induced changes in BH3 profiles between mouse mammary tumor cells (y-axis) and healthy human foreskin fibroblasts.
• FIGs. 4A-4E depict exemplary BH3 profiling of adult mouse hepatocytes.
• the loss of cytochrome c from mitochondria was measured in response to the synthetic BH3 peptides.
• Cytochrome c immunofluorescence was assessed using the synthetic Bim BH3 peptide at 0.1 ⁇ (FIG. 4A), 1.56 ⁇ (FIG. 4B), 25 ⁇ (FIG. 4C), and 100 ⁇ (FIG. 4D).
• a corresponding dose-response curve is further depicted (FIG. 4E).
• FIGs. 5A-5E depicts examples of compounds that increase cell death sensitivity in adult mouse hepatocytes.
• the loss of cytochrome c from mitochondria was measured in response to DMSO control (FIG. 5A), Navitoclax (FIG. 5B), Doxorubicin (FIG. 5C), and Tanespimycin (FIG. 5D).
• Increase in cell death sensitivity is indicated by loss of cytochrome c, which is quantified as an increase in apoptotic sensitivity, or delta priming (e.g. , delta percent priming), and is depicted in FIG. 5E.
• the present disclosure relates to the discovery that the principles of dynamic BH3 profiling can be utilized to assess the toxicity of an agent in non-cancerous cells.
• the disclosure provides methods for quickly and effectively determining how an agent alters the apoptotic sensitivity of non-cancerous cells. For example, many current means of assessing drug toxicity during drug development is limited because pre-clinical toxicity largely relies on testing in mammals, which can be expensive, time consuming, and unreliable. Dynamic BH3 profiling methods provided herein provide inexpensive and robust alternatives to traditional pre-clinical toxicity testing.
• dynamic BH3 profiling may be carried out on normal cells, e.g., a panel of normal cells, to perform toxicity screens of drugs on normal primary tissues.
• a particular environment e.g. , a room, a building, a street, a city
• Dynamic BH3 profiling methods provided herein permit profiling of normal cells to rapidly detect the presence of toxic agents (e.g., radiation, gas, biological agents, etc.) in an environment.
• the disclosure provides a method of screening a plurality of agents for determining toxicity, including: a) providing a plurality of agents; b) providing a sample of cells, wherein the cells are non-cancerous; c) providing a test aliquot of the sample of cells for each of the plurality of agents; d) separately contacting each test aliquot with its respective agent; e) providing a control aliquot of the sample of cells, wherein the control aliquot is not contacted with any of the plurality of agents; f) permeabilizing the cells in each aliquot; g) contacting the permeabilized cells with a pro-apoptotic BH3 domain peptide; h) determining a value for percent BH3 domain peptide-induced MOMP in the cells in each of the test aliquots; i) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the control aliquot; and j) determining a value for delta percent priming for
• the disclosure provides a method of predicting toxicity of an agent to a tissue, said method comprising: a) providing an agent; b) providing a plurality of cell samples comprising non-cancerous cells, wherein each cell sample is obtained from a tissue; c) providing a test aliquot of each of the plurality of cell samples; d) separately contacting each test aliquot with the agent; e) providing a control aliquot of each of the plurality of cell samples, wherein the control aliquot is not contacted with the agent (e.g., the control aliquot contains cells not contacted with the agent or contains cells from an animal not contacted with the agent); f) permeabilizing the cells in each test aliquot and control aliquot; g) contacting the permeabilized cells with a pro-apoptotic BH3 domain peptide; h) determining a value for percent BH3 domain peptide-induced MOMP in the cells in each test aliquot; i) determining a value for
• the non-cancerous cells are normal healthy cells (e.g., cells that do not have any patent or latent pathological condition).
• the noncancerous cells are infected with an infectious agent, e.g., a virus or an intracellular bacterium.
• the non-cancerous cells are from an organ that is otherwise not functioning normally.
• the non-cancerous cells are subject to stress, e.g., vascular stress such as hypoxia, stroke, myocardial infarction, among others.
• the cells are mammalian cells.
• the cells are derived from samples obtained by biopsy or autopsy of an animal.
• the cells are non-malignant human or mouse primary cells.
• provided methods further include k) providing a sample of cells, wherein the cells are cancerous; 1) providing a test aliquot of the sample of cancerous cells for each of the plurality of agents; m) separately contacting each test aliquot with its respective agent; n) providing a control aliquot of the sample of cancerous cells, wherein the control aliquot is not contacted with any of the plurality of agents; o) permeabilizing the cancerous cells in each aliquot; p) contacting the permeabilized cancerous cells with a pro- apoptotic BH3 domain peptide; q) determining a value for percent BH3 domain peptide- induced MOMP in the cancerous cells in each of the test aliquots; r) determining a value for percent BH3 domain peptide-induced MOMP in the cancerous cells in the control aliquot; and s) determining a value for delta percent priming for each of the test aliquots, wherein delta percent priming is the difference between
• the method further comprises conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, or at least 200%, greater than the delta percent priming in the non-cancerous cells.
• the method further comprises conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is at least 2- fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8- fold, at least 9-fold, or at least 10-fold greater than the delta percent priming in the noncancerous cells.
• the cancerous cells comprise an immortalized cancer cell line. In some embodiments, the cells are immortalized mouse or human cancer cell lines.
• Established cancer cell lines are well-known in the art and include for example pancreatic cancer cell lines (e.g., YAPC, Panc02.03 and SU86.86, etc.), breast cancer cell lines (e.g., AU565, BT-20, CAL-120, HMEL and KPL- 1, etc.), kidney cancer lines (e.g., 769-P, ACNH, HEK TE, SLR 20 and UMRC2, etc.), bone cancer cell lines (e.g., CAL-78, HOS, MG-63 and SK-ES-1, etc.) and lymphoid cancer cell lines (e.g., AML- 193, BDCM, CML-T1 and JM1, etc.).
• pancreatic cancer cell lines e.g., YAPC, Panc02.03 and SU86.86, etc.
• breast cancer cell lines e.g., AU565, BT-20, CAL-120, HMEL and KPL- 1, etc.
• kidney cancer lines e.g
• the cells are derived from a subject.
• cancer cells may be isolated from a subject by a surgical technique (e.g., biopsy).
• the cells are primary tumor cells.
• the cells comprise a patient-derived xenograft (PDX).
• PDX patient-derived xenograft
• the term "patient-derived xenograft" (PDX) refers to tissue generated by the implantation of cancerous primary tumor into an immunodeficient mouse.
• contacting the cells includes culturing the cells in the presence or absence of an agent.
• the cells are cultured in a culture medium under suitable culture conditions in the presence or absence of an agent.
• a "culture medium” (also referred to herein as a "cell culture medium” or “medium”) is a medium for culturing cells containing nutrients that maintain cell viability and support proliferation. The disclosure contemplates various parameters and conditions for culturing the cell.
• the culture medium contains serum.
• the cell culture medium may contain any of the following nutrients in appropriate amounts and combination: salt(s), buffer(s), amino acids, glucose or other sugar(s), antibiotics, serum or serum replacement, and other components such as peptide growth factors, etc.
• Cell culture media are known in the art and may be classified as natural or artificial media. Examples of cell culture media include but are not limited to Minimum Essential Medium (MEM), Dulbecco' s Modified Eagle' s Medium
• DMEM Roswell Park Memorial Institute Medium
• RPMI Roswell Park Memorial Institute Medium
• the cells are contacted with an agent, e.g., cultured in the presence of an agent, for at least 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 20 hours, 1 day, at least 2 days, at least 3 days, or at least 4 days.
• the cells are contacted with an agent, e.g., cultured in the presence of an agent, for 48 hours or less, 36 hours or less, 24 hours or less, or 12 hours or less.
• the disclosure provides a method of predicting toxicity of an agent, said method comprising: a) contacting a non-human animal with a sublethal dose of an agent; b)sacrificing the animal; c) providing one or more cell samples, wherein each cell sample is obtained from a tissue from the animal; d) providing a test aliquot of each of the one or more cell samples; e) separately contacting each test aliquot with the agent; f) providing a control aliquot of each of the one or more cell samples, wherein the control aliquot is not contacted with the agent; g) permeabilizing the cells in each aliquot; h) contacting the permeabilized cells with a pro-apoptotic BH3 domain peptide; i) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the test aliquot; j) determining a value for percent BH3 domain peptide-induced MOMP in the cells in the control aliquot; and k)
• a subject is preferably a mammal.
• the mammal is, for example, a human, non-human primate, mouse, rat, dog, cat, horse, or cow.
• the mammal is a non-human primate or a rodent.
• the subject is a genetically-modified animal.
• a mouse can be genetically engineered to develop a particular cancer.
• the subject has not been previously diagnosed as having cancer.
• the subject has been previously diagnosed as having cancer, and possibly has already undergone treatment for cancer.
• aspects of the disclosure can relate to contacting a subject (e.g. , a non-human animal) with a sublethal dose of an agent.
• the non-human animal can be contacted with the agent by methods known in the art.
• the agent is administered to the animal, e.g., by injection, inhalation, topical administration, or oral administration.
• the agent can be administered by topical administration (e.g. , epicutaneous or inhalational administration), enteral administration (e.g. , oral, gastric, or rectal administration), or parenteral administration (e.g. , intravenous, intra-arterial, intraosseous, intra-muscular, intracerebral, intracerebroventricular, intrathecal, or
• Cell sensitivity to the agent is determined by contacting the cells or cellular component (e.g., mitochondria) with a BH3 profiling buffer and a BH3 domain peptide from the pro-apoptotic BCL-2 family or small molecules with direct mitochondrial activity. This includes, but is not limited to ABT-199, ABT-263, ABT-737, WEHI-539, A- 1210477, and ABT- 199.
• the ability of BH3 peptides to induce MOMP is measured in the cells (or cellular component, e.g., mitochondria) exposed to the agent and the control cells (or cellular component, e.g., mitochondria) not exposed to the agent.
• An increase in BH3 peptide- induced MOMP in the cells cultured in the presence of the agent compared to the amount of BH3 domain peptide induced MOMP in the cells cultured in the absence of the agent indicates that the cells are responsive (e.g., cell death will be induced) to the agent.
• No change in MOMP in the cells cultured in the presence of the agent compared to the amount of BH3 domain peptide induced MOMP in the cells cultured in the absence of the agent indicates that the drug has no effect on inducing cell death.
• a decrease in MOMP in the cells cultured in the presence of the agent compared to the amount of BH3 domain peptide induced MOMP in the cells cultured in the absence of the agent indicates that the agent has a desensitizing or protective effect on the cells.
• the difference in the level of BH3 domain peptide-induced MOMP of cells that have been exposed to the agent as compared to the level of BH3 domain peptide-induced MOMP of cells that have not been exposed to the agent is statistically significant.
• statistically significant it is meant that the alteration is greater than what might be expected to happen by chance alone.
• Significant differences may be identified by using an appropriate statistical test. Tests for statistical significance are well known in the art and are exemplified in Applied Statistics for Engineers and Principles by Petruccelli, Chen and Nandram 1999 Reprint Ed.
• BH3 Profiling Buffer refers to an aqueous solution comprising a sugar, a pH buffer, salts, chelators and a carbon source for the electron transport chain that is useful for performing measurements of MOMP.
• Pro-apoptotic BCL-2 BH3 proteins and peptides include: Bcl-2 interacting mediator of cell death (BIM); a mutant thereof (BIM AV); BH3 interacting domain death agonist (BID); Bcl-2-associated death promoter (BAD); NOXA; p53 up-regulated modulator of apoptosis (PUMA); Bcl-2-modifying factor (BMF) and harakiri (HRK) (See, Table 1).
• the method comprises permeabilizing the cell after, prior to, or simultaneously when contacting with the BH3 domain peptide.
• permeabilization refers to the process of treating a cell with a reagent such that the cell membrane becomes permeable without permeabilizing the mitochondrial outer membrane.
• Reagents used for permeabilization include organic solvents (e.g., acetone and methanol) and detergents (e.g., digitonin, saponin, Triton X- 100 and Tween-20).
• the cell is permeabilized to permit the BH3 peptides access to the mitochondria.
• Cells are permeabilized by methods known in the art.
• the cell are permeabilized by contacting the cell with digitonin, saponin, methanol, Triton X- 100 or other art-recognized cell-permeabilization agents.
• the BH3 profiling buffer comprises the permeabilizing reagent, such as digitonin or saponin.
• permeabilized cells are contacted with the pro-apoptotic BH3 domain peptide for 3 hours or less, 2 hours or less, or 1 hour or less.
• automated liquid handling systems are generally utilized for high throughput drug screening.
• Automated liquid handling systems utilize arrays of liquid dispensing vessels, controlled by a robotic arm, to distribute fixed volumes of liquid to the wells of an assay plate. Generally, the arrays comprise 96, 384 or 1536 liquid dispensing tips.
• Non-limiting examples of automated liquid handling systems include digital dispensers (e.g., HP D300 Digital Dispenser) and pinning machines (e.g., MULTI-BLOTTM Replicator System, CyBio, Perkin Elmer Janus).
• Non-automated methods are also contemplated by the disclosure, and include but are not limited to a manual digital repeat multichannel pipette.
• the MOMP is measured.
• Outer membrane permeabilization can be measured in several ways. For example, outer membrane permeabilization can be measured by determining the loss of mitochondrial membrane potential. Loss of mitochondrial membrane potential is measured by, for example, treating the cells with a potentiometric or radiometric dye.
• potentiometric dyes include, but are not limited to, the fluorescent JC- 1 probe (5,5',6,6'-tetrachloro-l,l',3,3'- tetraethylbenzimidazolylcarbocyanine iodide) or dihydrorhodamine 123, or
• TMRM tetramethylrhodamine methyl ester
• TMRE tetramethylrhodamine ethyl ester
• outer membrane permeabilization is determined by measuring the release of a molecule from the mitochondrial intermembrane space or by measuring the retention of a molecule from the mitochondrial intermembrane space.
• a molecule from the mitochondrial intermembrane space examples include cytochrome c, SMAC/Diablo, Omi, adenylate kinase-2, or apoptotic-inducing factor (AIF).
• AIF apoptotic-inducing factor
• the release or retention of a molecule from the mitochondrial intermembrane space can be measured by methods well- known in the art.
• the release or retention of a molecule can be measured by using an antibody to the molecule, i.e., an antibody to cytochrome c, SMAC/Diablo, Omi, adenylate kinase-2 or apoptotic-inducing factor (AIF).
• Detection can be for example, by
• ELISA ELISA
• FACS fluorescence-activated cell sorting
• immunoblot immunofluorescence
• immunohistochemistry plate fluorimetry
• fluorescent imaging fluorescent imaging or automated image analysis. Analysis of the cells can be manually accomplished using a microscope or automated for example by using software such as Cellprofiler to locate nuclei.
• the cells are fixed prior to measuring outer membrane permeabilization.
• Mitochondrial outer membrane permeabilization can be measured at the single cell level or multi-cell level. Additionally, some of the methods disclosed herein allow for subpopulations of cells to be assayed. For example, a tumor-specific or tumor-associated marker (e.g., EpCam) can be used to identify tumor cells. This allows for the ability to discriminate between normal and tumor cells. MOMP is then measured as described herein in the tumor cells.
• a tumor-specific or tumor-associated marker e.g., EpCam
• measurements of MOMP can be normalized to facilitate comparative assessments.
• some aspects of the methods provided herein relate to screening a plurality of agents for determining toxicity by determining BH3 domain peptide-induced MOMP in a cell for each of the plurality of agents.
• BH3 domain peptide-induced MOMP can be measured by methods known in the art. Normalization of measured BH3 peptide-induced MOMP can be performed by methods known in the art, such as described in Ryan, J., Letai, A. (2013) Methods 61(2): 156-164 and Friedman, A., Letai, A., Fisher, D., Flaherty, K.
• the following is an exemplary, non-limiting, method of normalizing BH3 domain peptide-induced MOMP measurements: A test aliquot of a sample of cells is contacted with an agent. The test aliquot is contacted with a pro-apoptotic BH3 domain peptide. The BH3 domain peptide-induced MOMP in these "treated" cells is measured as described herein and by methods known in the art (e.g., by measuring mitochondrial membrane polarization, by measuring the release of a molecule from the mitochondrial intermembrane space, or by measuring the retention of a molecule from the mitochondrial intermembrane space). A separate aliquot of the sample of cells, a control aliquot, is not contacted with the agent.
• the control aliquot is contacted with a pro-apoptotic BH3 domain peptide.
• the BH3 domain peptide-induced MOMP in these "untreated” cells is measured as described herein and by methods known in the art.
• the measured MOMP in "treated” and “untreated” cells can be compared by measuring a maximum range for MOMP measurements in a given sample of cells.
• the maximum range for MOMP measurements can be determined by measuring an "upper limit” value for MOMP and a "lower limit” value for MOMP.
• an "upper limit” value for MOMP measurements can be obtained by contacting a separate aliquot of the sample of cells with a molecule that is known to be toxic to a cell and measuring a value for MOMP.
• the molecule that is known to be toxic to a cell is an uncoupling agent such as carbonyl cyanide-/?-trifluoromethoxyphenylhydrazone (FCCP) or carbonyl cyanide m-chlorophenyl hydrazine (CCCP).
• FCCP carbonyl cyanide-/?-trifluoromethoxyphenylhydrazone
• CCCP carbonyl cyanide m-chlorophenyl hydrazine
• a "lower limit" value for MOMP measurements can be obtained by measuring a value for MOMP in a separate aliquot of cells that have not been contacted with an agent, a pro-apoptotic BH3 domain peptide, or a molecule that is known to be toxic to a cell.
• the value for percent BH3 domain peptide- induced MOMP can be calculated for the test aliquot and the control aliquot using the equation:
• % O represents the value for percent BH3 domain peptide-induced MOMP
• Sample represents either the value for BH3 domain peptide-induced MOMP measured in the test aliquot or the value for BH3 domain peptide-induced MOMP measured in the control aliquot
• UpperLimit represents the measured “upper limit” value for MOMP
• “LowerLimit” represents the measured “lower limit” value for MOMP.
• methods provided herein relate to determining the toxicity of an agent in a sample of cells.
• the toxicity of the agent can be determined by determining a value for delta percent priming.
• delta percent priming refers to the extent to which an agent shifts a cell closer to the threshold of apoptosis.
• normalized values of MOMP e.g., percent BH3 domain peptide-induced MOMP, or "% 0 P" are used to determine a value for delta percent priming.
• Determining a value for delta percent priming can provide an assessment of the toxicity attributable to a particular agent in a given sample of cells. As described herein, the greater the value for delta percent priming of a cell contacted with an agent, the greater the toxicity of the agent to the cell. Thus, in some embodiments, the toxicity of a first agent in a sample of cells can be compared to the toxicity of a second agent in the sample of cells by comparing the value for delta percent priming determined for each agent. Such methods can be useful to screen for agents that are more toxic to a given sample of cells or less toxic to a given sample of cells, depending upon the outcome desired by a practitioner.
• methods provided herein relate to determining the toxicity of an agent in each of a plurality of cell samples.
• the toxicity of the agent in a first cell sample can be compared to the toxicity of the agent in a second cell sample by comparing the value for delta percent priming determined for the agent in each of the cell samples.
• Such methods can be useful to assess the toxicity of a given agent across different cell types (e.g., cells obtained from different tissue types).
• the disclosure provides methods for determining the toxicity of an agent to a sample of cells, wherein the cells are non-cancerous.
• a delta percent priming of greater than 20% indicates that the agent is toxic to the non-cancerous cells.
• a delta percent priming of greater than 0% indicates that the agent is toxic to the non-cancerous cells.
• methods provided herein further comprise conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming in the non-cancerous cells is 20% or less.
• in vivo or in vitro toxicity testing is conducted with an agent if the delta percent priming in the non-cancerous cells is 20% or less, 18% or less, 16% or less, 14% or less, 12% or less, 10% or less, 8% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, 0.9% or less, 0.8% or less, 0.7% or less, 0.6% or less, 0.5% or less, 0.4% or less, 0.3% or less, 0.2% or less, 0.1% or less, or 0%.
• aspects of the disclosure provide methods relating to determining toxicity of an agent in a sample of non-cancerous cells.
• methods provided herein can further comprise steps relating to determining toxicity of the agent in a sample of cancerous cells.
• the toxicity of the agent in the cancerous cells can be assessed using methods provided herein, for example, by determining a value for delta percent priming.
• a delta percent priming of greater than 20% indicates that the agent is toxic to the cancerous cells.
• a delta percent priming of greater than 0% indicates that the agent is toxic to the cancerous cells.
• methods provided herein further comprise conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming in the cancerous cells is greater than 20%.
• in vivo or in vitro toxicity testing is conducted with an agent if the delta percent priming in the cancerous cells is greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 45%, greater than 50%, greater than 55%, greater than 60%, greater than 65%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, greater than 98%, greater than 99%, or 100%.
• methods provided herein further comprise conducting in vivo or in vitro toxicity testing with the agent if the delta percent priming in the non-cancerous cells is lower than the delta percent priming in the cancerous cells.
• in vivo or in vitro toxicity testing can comprise methods provided herein and methods known in the art related to determining the toxicity of an agent.
• certain aspects of the disclosure relate to the screening of a plurality of agents for determining toxicity in a sample of non-cancerous cells.
• the agent can be selected for further toxicity testing (e.g., in vivo or in vitro toxicity testing).
• it can be useful to conduct further testing comprising determining the toxicity of the agent in a different sample of cells (e.g., cancerous cells, cells obtained from a different type of tissue, cells obtained from a different subject).
• it can be useful to conduct further testing comprising determining the toxicity of the agent in a subject (e.g. , by administering the agent to the subject, by contacting the agent with a sample of cells obtained from the subject).
• an agent e.g. , a therapeutic agent, a cancer therapeutic
• an agent e.g. , a therapeutic agent, a cancer therapeutic
• non-cancerous e.g. , healthy
• such an agent would manifest as having a minimal value for delta percent priming in non-cancerous cells and a maximal value for delta percent priming in cancerous cells.
• the disclosure relates to drug discovery.
• methods described by the disclosure are useful for screening large libraries of candidate agents to identify new drugs that do not move cells closer to programmed cell death, e.g., agents that are not toxic to the cells.
• the library of candidate agents includes 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 150 or more, 200 or more, 250 or more, or 300 or more agents.
• an agent includes a compound. In some embodiments, an agent includes more than one compound.
• Exemplary candidate agents include, but are not limited to small organic molecules, small inorganic molecules, peptides, proteins, protein analogs, enzymes, nucleic acids, nucleic acid analogs, antibodies, antigens, hormones, lipids, polysaccharides, growth factors, viruses, cells, bioactive agents, pharmaceutical agents, and combinations and prodrugs thereof.
• an agent is an anticancer agent, such as, a chemotherapeutic agent.
• Further exemplary candidate agents include, but are not limited to, gases, fine particles, radiation, electromagnetic radiation, and aerosols.
• a candidate agent is a chemotherapeutic agent.
• chemotherapeutic agents include small molecules, peptides or proteins (e.g., peptide antibiotics and antibodies) and RNA-interference (RNAi) molecules.
• small molecule chemotherapeutic agents include alkylating agents (cyclophosphamide, chlormethine, temozolomide), anthracyclines (daunorubicin, doxorubicin, mitoxantrone), taxanes (paclitaxel, docetaxel), histone deacetylase inhibitors (vorinostat, romidepsin), topoisomerase I II inhibitors (irinotecan, topotecan, etoposide), kinase inhibitors (gefitinib, imatinib, bortezomib), nucleotide analogs and precursor analogs (azacitidine, fluorouracil, methotrexate), platinum-based agents (cisplatin, carboplatin), retinoids (alitretinoin, bexarotene) and vinca alkaloids (vinblastine, vindesine, vinorelbine).
• alkylating agents cyclophospham
• RNAi molecules examples include bleomycin, dactinomycin, antitumor antibodies (anti-HER2/neu, alemtuzumab, trastuzumab, brentuximab).
• chemotherapeutic RNAi molecules as RNAi molecules that target expression of genes related to cancer.
• RNAi molecules directed against HoxAl can inhibit mammary tumor cell formation, as disclosed by Brock et al. Sci Transl Med 6: 217ra2 (2014).
• chemotherapeutic agents include, but are not limited to, kinase inhibitors, apoptosis inducers, angiogenesis inhibitors, and monoclonal antibodies.
• methods provided herein can be useful for determining the toxicity of an environment or environmental condition.
• the environment comprises an agent that may or may not be toxic to a cell.
• agents in an environment or environmental condition can include, without limitation, gases, fine particles, radiation, electromagnetic radiation, and aerosols.
• Environmental agents are known in the art, for example, as provided by the National Institute of Environmental Health Sciences (www.niehs.nih.gov/health/topics/agents/).
• cells can be contacted with the agent using various methods known in the art and described herein.
• a cell can be exposed to an environment that is suspected of being radioactive or known to be radioactive.
• the agent being tested for toxicity could comprise radiation (e.g. , alpha particles, beta particles, positron particles, gamma rays, X-rays, and neutrons).
• the disclosure relates to personalized medicine. In some aspects, the disclosure relates to personalized medicine. In some
• methods described herein are useful for the customization of chemotherapeutic regimens.
• methods provided herein can relate to determining the toxicity of an agent in both non-cancerous cells and cancerous cells.
• the noncancerous cells and the cancerous cells are obtained from a subject.
• the agent can be identified as being more or less appropriate for treating the subject.
• the agent becomes more appropriate for treating the subject as the ratio of delta percent priming in cancerous cells to delta percent priming in non-cancerous cells increases.
• an agent that has minimal toxicity (e.g. , minimal value for delta percent priming) in non-cancerous cells of the patient and maximal toxicity (e.g. , maximal value for delta percent priming) in cancerous cells of the patient.
• minimal toxicity e.g. , minimal value for delta percent priming
• maximal toxicity e.g. , maximal value for delta percent priming
• the disclosure provides methods of determining the toxicity of an agent, wherein the toxicity of the agent is determined by comparing BH3 domain peptide- induced MOMP in test cells contacted with the agent to BH3 domain peptide-induced MOMP to control cells not contacted with the agent.
• the control cells have not been contacted with any agent.
• the control cells have been contacted with buffer or solvent, e.g., buffer or solvent used as a vehicle for the agent.
• the test cells can be contacted with an agent that has been dissolved in a suitable buffer or solvent (e.g. , DMSO), and the control can be contacted with a suitable buffer or solvent (e.g. , DMSO) lacking the agent.
• methods described herein can be suitable for a high-throughput format.
• aspects of the disclosure relate to methods of screening of a plurality of agents to determine toxicity.
• the plate comprises an agent.
• the plate comprises a plurality of agents.
• the plate may be used to test a panel of agents, each well comprising an agent.
• one or more wells of the plate do not comprise an agent.
• control aliquots are not contacted with an agent.
• one or more wells designated for control aliquots can comprise buffer or solvent (e.g. , DMSO).
• the multi-well plate comprises a BH3 domain peptide.
• the BH3 domain peptide is derived from the BH3 domain of a BID, a BIM, a BAD, a NOXA, a PUMA a BMF, or a HRK polypeptide.
• the BH3 domain peptide is selected from the group consisting of SEQ ID NO: 1- 15.
• the plate comprises more than one BH3 domain peptide.
• a plate comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 BH3 domain peptides.
• one or more wells of the plate do not comprise a BH3 domain peptide.
• aliquots are not contacted with a BH3 domain peptide.
• one or more wells designated for lower limit measurements can comprise buffer or solvent (e.g. , DMSO).
• the cells do not need to be removed from a culture plate to perform dynamic BH3 profiling described herein.
• the presence of cell culture media and serum has been demonstrated not to interfere with the ability of BH3 peptides to induce mitochondrial outer membrane permeabilization.
• wash steps where there is little residual volume above the cells have been demonstrated to be unnecessary. Instead, the cells can be successively treated in the plate well with the drug and the BH3 domain peptide.
• the cells are cultured on an adhesive solid surface in a culture medium having serum in the presence and absence of an agent.
• the method further comprises washing the culture media from the cells prior to contacting the cells with the BH3 profiling buffer and the pro-apoptotic BH3 domain peptide.
• the adhesive solid surface is coated with one or more pro-adhesive compounds.
• the one or more pro-adhesive compounds is an extracellular matrix (ECM) protein.
• ECM extracellular matrix
• the ECM protein is selected from the group consisting of collagen 1, laminin, collagen 4 and fibronectin.
• the one or more pro-adhesive compounds is an antibody.
• the one or more pro-adhesive compounds is streptavidin.
• the BH3 profiling buffer is Derived from Trehalose Experimental Buffer (DTEB) or Mitochondria Experimental Buffer (MEB).
• the cells are permeabilized after, prior to, or simultaneously when contacting with the BH3 domain peptide.
• the BH3 profiling buffer is supplemented with a permeabilizing agent.
• the permeabilizing agent is digitonin or saponin
• the term "BH3 Profiling Buffer” refers to an aqueous solution comprising a sugar, a pH buffer, salts, chelators and a carbon source for the electron transport chain that is useful for performing measurements of MOMP.
• the BH3 Profiling Buffer is a Derived from Trehalose Experimental Buffer (DTEB).
• the BH3 Profiling Buffer is a Mitochondria
• DTEB is comprised of 135 mM trehalose, 10 mM Hepes, 50 mM KC1, 20 ⁇ EGTA, 20 ⁇ EDTA, 0.1 % BSA and 5mM Succinate.
• MEB is comprised of 150 mM mannitol, 10 mM Hepes, 50 mM KC1, 20 ⁇ EGTA, 20 ⁇ EDTA, 0.1 % BSA and 5mM Succinate. Sucrose and other sugars may be used in the place of mannitol. Some increases in KC1 are tolerated, however can be detrimental to BH3 profiling. Concentrated buffers (2X-5X) involve proportionally increasing the concentration of the above reagents
• the BH3 profiling buffer is added at a concentration of 2X, 3X or 4X. In some embodiments of any of the provided methods, the BH3 profiling buffer is added at a concentration of 2X and the amount of BH3 domain peptide induced MOMP is measured by microscopy. In some embodiments of any of the provided methods, the BH3 profiling buffer is added at a concentration of 3X or 4X and the amount of BH3 domain peptide induced MOMP is measured by Fluorescence-activated cell sorting (FACS).
• FACS Fluorescence-activated cell sorting
• automated liquid handling systems are generally utilized for high throughput drug screening.
• Automated liquid handling systems utilize arrays of liquid dispensing vessels, controlled by a robotic arm, to distribute fixed volumes of liquid to the wells of an assay plate.
• the arrays comprise 96, 384 or 1536 liquid dispensing tips.
• Non-limiting examples of automated liquid handling systems include digital dispensers (e.g., HP D300 Digital Dispenser) and pinning machines (e.g., MULTI-BLOTTM Replicator System, CyBio, Perkin Elmer Janus).
• Non- automated methods are also contemplated by the disclosure, and include but are not limited to a manual digital repeat multichannel pipette.
• a Pro-apoptotic BCL-2 BH3 domain peptide is less than 195 amino acids in length, e.g., less than or equal to 150, 100, 75, 50, 35, 25 or 15 amino acid in length.
• Non-limiting examples of pro-apoptotic BCL-2 BH3 peptides include: Bcl-2 interacting mediator of cell death (BIM); a mutant thereof (BIM AV); BH3 interacting domain death agonist (BID); Bcl-2- associated death promoter (BAD); NOXA; p53 up-regulated modulator of apoptosis (PUMA); Bcl-2-modifying factor (BMF) and harakiri (HRK).
• a pro-apoptotic BCL-2 BH3 domain peptide includes the sequence of SEQ ID NO: 1-15 shown in Table 1.
• PUMA2A (SEQ ID NO: 16) is a negative control peptide.
• a BH3 domain peptide include a peptide which includes (in whole or in part) the sequence NH 2 -XXXXXXXXXLXXXDXXXX -COOH (SEQ ID NO: 17).
• X may be any amino acid.
• the BH3 domain peptides include at least 5, 6, 7, 8, 9, 15 or more amino acids of SEQ ID NO: 17.
• the BH3 domain peptides can be modified using standard modifications.
• Modifications may occur at the amino (N-), carboxy (C-) terminus, internally or a combination of any of the preceding. In one aspect described herein, there may be more than one type of modification on the polypeptide. Modifications include but are not limited to: acetylation, amidation, biotinylation, cinnamoylation, farnesylation, formylation, myristoylation, palmitoylation, phosphorylation (Ser, Tyr or Thr), stearoylation,
• the modified BH3 domain peptides retain the biological activity of BH3 domain peptides.
• retaining the biological activity it is meant that cell death is induced by the BH3 polypeptide, although not necessarily at the same level of potency as that of the naturally-occurring BH3 domain polypeptide.
• the terms induced and stimulated are used interchangeably throughout the specification.
• the BH3 domain peptide is attached to a transduction domain.
• a transduction domain directs a peptide in which it is present to a desired cellular destination.
• the transduction domain can direct the peptide across the plasma membrane, e.g., from outside the cell, through the plasma membrane, and into the cytoplasm.
• the transduction domain can direct the peptide to a desired location within the cell, e.g., the nucleus, the ribosome, the ER, mitochondria, a lysosome, or peroxisome.
• the transduction domain is derived from a known membrane-translocating sequence.
• transduction domain is a compound that is known to facilitate membrane uptake such as polyethylene glycol, cholesterol moieties, octanoic acid and decanoic acid.
• the transduction domain may be linked either to the N-terminal or the C- terminal end of BH3 domain peptide.
• the BH3 domain peptides and/or the transduction domain peptides can be polymers of L-amino acids, D-amino acids, or a combination of both.
• the BH3 domain peptides and/or the transduction domain peptides are cyclic peptides.
• Cyclic peptides are prepared by methods known in the art. For example, macrocyclization is often accomplished by forming an amide bond between the peptide N- and C-termini, between a side chain and the N- or C-terminus [e.g., with K3Fe(CN)6 at pH 8.5] (Samson et al., Endocrinology, 137: 5182-5185 (1996)), or between two amino acid side chains. See, e.g., DeGrado, Adv Protein Chem, 39: 51-124 (1988).
• BH3 domain peptides and/or the transduction domain peptides are prepared using modern cloning techniques, or may be synthesized by solid state methods or by site-directed mutagenesis.
• native BH3 domain peptides and/or transduction domain peptides can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques.
• BH3 domain polypeptides and/or transduction domain peptides are produced by recombinant DNA techniques.
• BH3 domain peptides and/or transduction domain peptides can be synthesized chemically using standard peptide synthesis techniques.
• the BH3 peptide maintains its secondary structure, e.g., - helical structure. Methods of helix stabilization are known in the art.
• An “isolated” or “purified” BH3 domain peptide is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the BH3 domain peptide is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized.
• kits for performing BH3 Profiling comprising a multi-well plate having an agent and a BH3 domain peptide.
• the kit comprises a multi-well plate having an agent.
• the agent is a chemotherapeutic agent.
• the kit comprises a multi-well plate having at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 agents.
• the kit comprises a multi- well plate, wherein each well of the plate comprises a different agent.
• the kit comprises a multi-well plate having a BH3 domain peptide.
• the BH3 domain peptide is derived from the BH3 domain of a BID, a BIM, a BAD, a NOXA, a PUMA a BMF, or a HRK polypeptide. In some embodiments, the BH3 domain peptide is selected from the group consisting of SEQ ID NO: 1-15.
• the kit further comprises a vial containing a BH3 profiling buffer.
• the vial is a glass or plastic vial.
• the vial comprises volumetric markings on its surface.
• the BH3 profiling buffer is supplemented with a permeabilizing agent.
• the BH3 profiling buffer is supplemented with a permeabilizing agent.
• permeabilizing agent is digitonin or saponin.
• the kit further comprises a potentiometric dye.
• the potentiometric dye is 5,5',6,6'- tetrachloro-1,1',3,3'- tetraethylbenzimidazolylcarbocyanine iodide (JC-1), dihydrorhodamine 123,
• the kit further comprises an antibody for cytochrome c, SMAC/Diablo, Omi, adenylate kinase-2 or apoptosis-inducing factor.
• the kit further comprises instructions for using the kit to predict the sensitivity of cells to an agent.
• Instructions are generally provided as a printed pamphlet or paper sheet but may also include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e.g., videotape, DVD, etc.), Internet, and/or web-based
• Example 1 Predicting toxicity in normal cells with dynamic BH3 profiling
• cytochrome c loss of cytochrome c from mitochondria was measured in response to the synthetic BH3 peptides.
• cytochrome c immunofluorescence FOGs. 1A-D
• FIG. IE standard deviations depicted as error bars. Note that at low concentrations of the Bim peptide there is little or no loss of cytochrome c, whereas at high peptide concentrations a complete loss of cytochrome c is observed.
• FIG. 2A depicts an exemplary histogram of the increases in cell death sensitivity (delta priming) represented by values of delta percent priming, with FIG 2B representing a zoomed view of the y-axis of the histogram
• FIG. 2 A comparison of drug induced changes in BH3 profiles between mouse mammary- tumor cells (y-axis) and healthy human foreskin fibroblasts (x-axis) is depicted in FIG. 3.
• y-axis mouse mammary- tumor cells
• x-axis healthy human foreskin fibroblasts
• BH3 profiling on healthy adult mouse hepatocytes was examined by measuring the loss of cytochrome c from mitochondria in response to the synthetic BH3 peptides. To do this, immunofluorescence for cytochrome c was assessed at increasing concentrations of Bim BH3 peptide (0.1 ⁇ (FIG. 4A), 1.56 ⁇ (FIG. 4B), 25 ⁇ (FIG. 4C), and 100 ⁇ (FIG. 4D)). A dose-response curve of cytochrome c loss is depicted in FIG. 4E. Note that at low concentrations of the Bim peptide, there is little or no loss of cytochrome c, whereas at high peptide concentrations a complete loss of cytochrome c is observed.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Toxicology (AREA)
• Cell Biology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Biotechnology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Food Science & Technology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• Microbiology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Apparatus Associated With Microorganisms And Enzymes (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=57198812

Family Applications (2)

Family Applications Before (1)

Country Status (6)

Cited By (14)

Families Citing this family (4)

Citations (3)

Family Cites Families (59)

• 2016
  • 2016-04-27 EP EP16787045.0A patent/EP3289094B1/en active Active
  • 2016-04-27 WO PCT/US2016/029495 patent/WO2016176288A1/en not_active Ceased
  • 2016-04-27 JP JP2017555779A patent/JP6814745B2/ja active Active
  • 2016-04-27 CA CA2983024A patent/CA2983024A1/en active Pending
  • 2016-04-27 JP JP2017555780A patent/JP6802185B2/ja active Active
  • 2016-04-27 US US15/569,851 patent/US20180120297A1/en not_active Abandoned
  • 2016-04-27 AU AU2016255749A patent/AU2016255749B2/en active Active
  • 2016-04-27 WO PCT/US2016/029510 patent/WO2016176299A1/en not_active Ceased
  • 2016-04-27 AU AU2016253957A patent/AU2016253957C1/en active Active
  • 2016-04-27 US US15/568,994 patent/US10761086B2/en active Active
  • 2016-04-27 EP EP16787039.3A patent/EP3288964B1/en active Active
  • 2016-04-27 CA CA2983022A patent/CA2983022C/en active Active
• 2020
  • 2020-07-27 US US16/939,736 patent/US11867688B2/en active Active
  • 2020-12-03 JP JP2020200805A patent/JP2021036915A/ja not_active Withdrawn
• 2021
  • 2021-02-26 US US17/186,344 patent/US20210255167A1/en not_active Abandoned

Patent Citations (3)

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events